Article
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
The lancet. Gastroenterology & hepatology - 1 Sept 2016
Asselah Tarik, Hézode Christophe, Qaqish Roula B, ElKhashab Magdy, Hassanein Tarek, Papatheodoridis George, Feld Jordan J, Moreno Christophe, Zeuzem Stefan, Ferenci Peter, Yu Yao, Redman Rebecca, Pilot-Matias Tami, Mobashery Niloufar
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial data for treatment remain limited. We assessed the combination of two direct-acting antivirals, ombitasvir (NS5A inhibitor) and paritaprevir (NS3/4A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.